On the contrary, THs may have an anticancer effect through inhibiting several “hallmarks of cancer cells”, such as: (i) genomic instability (e.g., through decreased Pituitary tumor-transforming gene 1 (PTTG1)) [39]; (ii) proliferation (e.g., through increased TGFb and Dickkopf 4 (DKK4), as well as decreased UHRF1); (iii) the reprogramming of metabolism (e.g., through increased Krueppel-like factor 9 (KLF9)) [40]; (iv) invasion and migration [41] (e.g., through increased DKK4, Wnt/b-catenin, and spondin 2 (Sp-2)) [42]. Here, UHRF1 is linked to cancer.